Search

Taladegib Pulmonary Fibrosis Treatment Patent Granted to Endeavor BioMedicines

The USPTO granted Patent US12605380B2 to Endeavor BioMedicines, Inc. covering methods of treating pulmonary fibrosis by administering taladegib. The patent, with 29 claims, classifies under CPC codes A61K 31/502 and A61P 11/00. The filing date was September 12, 2025, under Application No. 19327711.

Taladegib Patent Grant for Pulmonary Fibrosis Treatment

The USPTO granted patent US12605379B2 to Endeavor BioMedicines, Inc. covering methods of treating pulmonary fibrosis using taladegib. The patent includes 29 claims and covers CPC classifications A61K 31/502 and A61P 11/00. The filing date was September 12, 2025.